调节性T细胞与过敏性支气管哮喘  

Regulatory T cells and allergic bronchial asthma

作　　者：艾香艳[1] 时国朝[1] 

机构地区：[1]上海交通大学医学院附属瑞金医院呼吸科,200025

出　　处：《国际呼吸杂志》2009年第23期1438-1441,共4页International Journal of Respiration

摘　　要：这篇综述主要围绕调节性T细胞（regulatory Tcells，Treg）在过敏性支气管哮喘（简称哮喘）免疫发病机制中所承担的角色以及以其为靶点的过敏性哮喘的免疫治疗。研究者认为Treg是机体免疫反应程序中关键的调节因素，它能够通过各种机制诱导机体对自身抗原和过敏原产生免疫耐受，从而维持机体免疫系统的稳定。近年来，随着对Treg的研究不断深入，越来越多类型的Treg得以区分。研究发现其中主要是CD4＋Treg抑制机体对过敏原的免疫反应，而控制过敏性疾病（过敏性哮喘）的发生和发展。因此，这有力的证实了恢复和诱导过敏性哮喘患者体内Treg的功能是一种有效的潜在的治疗方法。The review focuses on the role of regulatory T cells（Treg） in the immune pathogenesis and immune therapy of allergic bronchioal asthma（asthma）. Researchers think Treg is a key immunoregulatory factor in the immune response, it can induce economy immune tolerance to autoantigen and allergens, thereby maintain the stability of immune system. In recent years, the general knowledge regarding the regulation of asthma and allergen immunotherapy by Treg, has rapidly increased. More and more different Treg subsets have been described. Studies found mainly CD4 ＋ Treg suppresses the immune response to allergens, and controls the occurrence and development allergic disease （allergic asthma）. Their therapeutic potential is perhaps best highlighted by evidence that therapies with demonstratedefficacy in allergic and asthmatic disease are associated with the inductionor restoration of Treg function.

关 键 词：调节性T细胞 过敏性哮喘 免疫治疗 

分 类 号：R562.25[医药卫生—呼吸系统] R392.4[医药卫生—内科学]